Literature DB >> 11445057

Atrial Fibrillation.

Jayant Bagai1, Boaz Avitall.   

Abstract

The conversion of atrial fibrillation (AF) to normal sinus rhythm should be attempted in patients who present with this condition, as long as the cure is not worse than the disease itself. In young patients with normal hearts, AF has a small impact on morbidity and mortality. The primary indication for conversion in this population is often symptoms. In contrast, in patients with diseased hearts or who are older than 65 years, maintaining sinus rhythm may have a favorable impact on stroke risk, ventricular function, and symptoms. In the absence of normal sinus rhythm, these patients should receive anticoagulants. Rate control is the preferred first-line strategy for asymptomatic patients and patients presenting with a history of long-standing, persistent AF, making conversion and maintenance of sinus rhythm unlikely. Rate control may be used in patients who develop AF during an acute systemic illness, which will likely terminate with time or therapy. Conversion to sinus rhythm should be considered in patients with a first episode of AF, as unconverted AF tends to perpetuate itself. Conversion can be attempted if the duration of AF is less than 48 hours or if the patient has received anticoagulants when the duration is not known. Other indications for cardioversion are prolonged episodes in patients with otherwise infrequent episodes of paroxysmal AF, and in patients who refuse to take anticoagulants or in whom anticoagulation is contraindicated. After the patient is converted to sinus rhythm, the decision to initiate chronic drug therapy should be based on the presence of other cardiac and medical diseases that increase the risk of recurrence and serious symptoms in case of recurrence (such as hypertrophic cardiomyopathy or mitral stenosis). It is acceptable to manage patients with new-onset AF and normal cardiac function with cardioversion alone and not initiate chronic antiarrhythmic therapy afterwards. However, in patients with abnormal hearts (coronary artery disease, hypertensive or mitral valvular heart disease, and cardiomyopathy) AF is likely to recur, and such patients should be placed on antiarrhythmic medication.

Entities:  

Year:  2001        PMID: 11445057     DOI: 10.1007/s11936-001-0089-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  34 in total

Review 1.  Antithrombotic therapy in atrial fibrillation.

Authors:  G W Albers; J E Dalen; A Laupacis; W J Manning; P Petersen; D E Singer
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Efficacy and cost analysis of ibutilide.

Authors:  A B Dunn; C M White; P Reddy; M S Chow; J Kluger
Journal:  Ann Pharmacother       Date:  2000-11       Impact factor: 3.154

Review 3.  The surgical management of atrial fibrillation.

Authors:  J L Cox; T M Sundt
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

4.  Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.

Authors:  D Roy; M Talajic; P Dorian; S Connolly; M J Eisenberg; M Green; T Kus; J Lambert; M Dubuc; P Gagné; S Nattel; B Thibault
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

5.  Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.

Authors:  S H Hohnloser; K H Kuck; J Lilienthal
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

6.  Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks.

Authors:  S Mittal; S Ayati; K M Stein; D Schwartzman; D Cavlovich; P J Tchou; S M Markowitz; D J Slotwiner; M A Scheiner; B B Lerman
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

7.  Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography.

Authors:  A L Klein; R A Grimm; I W Black; D Y Leung; M K Chung; S E Vaughn; R D Murray; D P Miller; K L Arheart
Journal:  Ann Intern Med       Date:  1997-02-01       Impact factor: 25.391

8.  First human experience with pulmonary vein isolation using a through-the-balloon circumferential ultrasound ablation system for recurrent atrial fibrillation.

Authors:  A Natale; E Pisano; J Shewchik; D Bash; R Fanelli; D Potenza; P Santarelli; R Schweikert; R White; W Saliba; L Kanagaratnam; P Tchou; M Lesh
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

9.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.

Authors:  M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

10.  The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators.

Authors:  G N Kay; K A Ellenbogen; M Giudici; M M Redfield; L S Jenkins; M Mianulli; B Wilkoff
Journal:  J Interv Card Electrophysiol       Date:  1998-06       Impact factor: 1.900

View more
  2 in total

1.  The natural history of atrial fibrillation in patients with permanent pacemakers: is atrial fibrillation a progressive disease?

Authors:  R A Veasey; C Sugihara; K Sandhu; G Dhillon; N Freemantle; S S Furniss; A N Sulke
Journal:  J Interv Card Electrophysiol       Date:  2015-07-03       Impact factor: 1.900

2.  Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: the TRENDS study.

Authors:  Taya V Glotzer; Emile G Daoud; D George Wyse; Daniel E Singer; Reece Holbrook; Khadeeja Pruett; Kenneth Smith; Christopher E Hilker
Journal:  J Interv Card Electrophysiol       Date:  2006-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.